Study establishes cell death as a driving force in glioblastoma
Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
Cannabidiol may be a promising agent for promoting dental biomineralization
In vitro tests indicate that cannabidiol can stimulate the biomineralization of teeth even under inflammatory conditions, ...
Aura Biosciences announces data from Phase 1 trial of bel-sar in NMIBC
Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...
Sacramento Bee5d
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations ...